Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 10% (peak at 1 hour) |
Protein binding | 70–80% |
Metabolism | extensive liver |
Elimination half-life | 1.7–6.9 hours |
Excretion | Kidney (68%) and bile duct (25%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.020.695 |
Chemical and physical data | |
Formula | C16H18N4O2 |
Molar mass | 298.346 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Piribedil (trade names Pronoran, Trivastal Retard, Trastal, Trivastan, Clarium and others) is an antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties.[2][3]